Spatial transcriptomics leverages omics techniques to extract transcriptome data while retaining the context of the original tissue, aiding disease research, biomarker development, and understandings of tissue structures and cellular heterogeneity.

Recent studies have used multiplex blood biomarker information from patients to distinguish individual patient subgroups for neurodegenerative diseases, helping to stratify patients by their pathology.

Diagnostic biomarkers offer a crucial means of tracking disease spread and progression. Here, we explore their application in age-related diseases, as well as inflammatory diseases such as Crohn’s.

Precision medicine involves tailoring a therapeutic to a patient’s disease: developing precision therapies require an accurate identification of therapeutic targets from available data.

The identification of novel clinical biomarkers is set to continue, with further research and investment in fields such as next-gen sequencing and miRNA targeting.

Anna Lyubetskaya, Senior Principal Scientist at Bristol Myers Squibb, leads a discussion on the industry landscape and ‘Current Status of Omics-Based Biomarkers.’

How do we implement the next generation of precision medicines and therapies to optimise patient experience? We sat down with senior representatives from Novartis, Merus, Labcorp, and Simcere Pharmaceuticals to discover the latest industry insights.